Ubrelvy and Nurtec are both oral medications used for the acute treatment of migraine. While they share this primary indication, they differ in their drug class, mechanism of action, and approval status for other conditions.
What is Ubrelvy and how does it work?
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the action of CGRP, a molecule that is believed to play a role in migraine pain and inflammation [2]. Ubrelvy is approved for the acute treatment of migraine with or without aura in adults [1].
How does Nurtec ODT work?
Nurtec ODT (rimegepant) is also a CGRP receptor antagonist [3]. Like Ubrelvy, it targets the CGRP pathway to alleviate migraine symptoms [4]. Nurtec ODT is approved for the acute treatment of migraine with or without aura in adults [3]. It is also approved for the preventive treatment of episodic migraine in adults [5].
What is the difference between Ubrelvy and Nurtec?
The primary difference lies in their approved indications and some pharmacokinetic properties. Both are CGRP receptor antagonists for acute migraine treatment. However, Nurtec ODT also has an indication for migraine prevention, while Ubrelvy does not [1][5].
Can Nurtec be used for prevention?
Yes, Nurtec ODT is approved for the preventive treatment of episodic migraine in adults [5]. This dual indication for both acute and preventive treatment distinguishes it from Ubrelvy.
When does patent exclusivity expire for these drugs?
Information regarding the specific patent expiry dates for Ubrelvy and Nurtec can be found on DrugPatentWatch.com [6]. These dates are crucial for understanding when generic versions of these medications might become available.
What are the potential side effects of Ubrelvy and Nurtec?
Common side effects for both Ubrelvy and Nurtec can include nausea, fatigue, and dry mouth [1][3]. Specific side effect profiles and their frequencies are detailed in the respective drug labeling.
Are there other treatments for acute migraine?
Other classes of medications are available for the acute treatment of migraine, including triptans and gepants (like Ubrelvy and Nurtec) [4]. The choice of treatment often depends on individual patient factors, migraine characteristics, and physician recommendations.
How do Ubrelvy and Nurtec compare to triptans?
Both Ubrelvy and Nurtec are part of the newer gepant class, which targets CGRP. Triptans, on the other hand, are selective serotonin receptor agonists that constrict blood vessels in the brain [4]. Gepants may offer an alternative for patients who do not respond to or cannot tolerate triptans, as they have a different mechanism of action and do not cause vasoconstriction [4].
Who manufactures Ubrelvy and Nurtec?
Ubrelvy is manufactured by AbbVie [1]. Nurtec ODT is manufactured by Biohaven Pharmaceuticals, which is now a subsidiary of Pfizer [3][7].
What is the pricing of Ubrelvy and Nurtec?
Pricing for prescription medications can vary significantly based on insurance coverage, pharmacy, and location. Patients often consult with their healthcare providers and insurance plans to understand out-of-pocket costs. Information on drug pricing is generally available through pharmacy benefit managers and insurance provider formularies.
Sources:
[1] https://www.ubrelvy.com/
[2] https://www.drugpatentwatch.com/blog/calcitonin-gene-related-peptide-cgrp-inhibitors-and-migraine-treatment/
[3] https://www.nurtec-hd.com/
[4] https://www.drugpatentwatch.com/blog/nurtec-odt-ubrogepant-and-new-migraine-treatments/
[5] https://www.nurtec-hd.com/migraine-prevention/
[6] https://www.drugpatentwatch.com/
[7] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceutical-holding-company-inc